Special Issue "Improving Medication Safety: Role of Providers, Patients and Technology"

A special issue of Pharmacy (ISSN 2226-4787).

Deadline for manuscript submissions: 30 November 2018

Special Issue Editors

Guest Editor
Assoc. Prof. Dr. Jimmy Jose

School of Pharmacy, University of Nizwa, Sultanate of Oman, Nizwa, Oman
Website | E-Mail
Interests: drug safety; intensive monitoring studies in drug safety; patient education on drug safety; knowledge, attitude and practice of public on drug use; patient medication adherence
Guest Editor
Dr. Muhammad Abdul Hadi

Leicester School of Pharmacy, De Montfort University, Leicester, UK
Website | E-Mail
Interests: health services research; medication safety; medicines optimization; pharmacy practice; pharmacy education

Special Issue Information

Dear Colleagues,

Ensuring safe and effective use of medicines is critical in achieving desired therapeutic outcomes. Healthcare providers have been at the center of attention in the drug safety debate, but there is a growing recognition of the role of patients in drug safety. The exclusive role of patients in improving the safe use of drugs requires continuous emphasis as all the efforts from other sources will be in vain unless the end users play an active role in the whole process. Health care technologies can greatly influence the efforts in improving safety. In the present digital era, the influence of various information sources on the safety of medications at the level of providers as well as patients is worth appraising.

This Special Issue on “Improving Medication Safety—Role of Providers, Patients and Technology” would like to invite authors from across the world to contribute original research and review articles, both narrative and systematic, short communications, editorials, and commentaries. The special interest of this issue is on identifying and representing the unique role of various health care providers and patients themselves in improving medication safety. The impact and role of health care technologies, as well as information sources on medication safety, are of additional interest as part of this themed issue.

We welcome submission of manuscripts which deal with a broad range of topics, such as:

  • Practical approaches or interventions which influence/improve medication safety
  • Unique role of providers; pharmacists, clinicians, nurses and other health care providers in medication safety
  • Multidisciplinary approaches/systems to enhance medication safety
  • Educational initiatives to improve medication safety
  • Influence of sharing of information on medication safety on the patients and public
  • Various Information sources and its exclusive influence on medication safety in real life
  • Role of technology at various stages of medication safety in clinical practice

Assoc. Prof. Dr. Jimmy Jose
Dr. Muhammad Abdul Hadi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmacy is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Harms Reduction
  • Healthcare Technology
  • Health Information Sources
  • Medication Safety
  • Medicines Optimization 
  • Patient-provider Partnership
  • Multi-disciplinary Approaches 

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessReview Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients
Received: 25 April 2018 / Revised: 1 June 2018 / Accepted: 21 June 2018 / Published: 27 June 2018
PDF Full-text (305 KB) | HTML Full-text | XML Full-text
Type 2 Diabetes Mellitus (T2DM) is the most common form of diabetes mellitus and accounts for about 95% of all diabetes cases. Many newer oral as well as parenteral antidiabetic drugs have been introduced in to the market in recent years to control
[...] Read more.
Type 2 Diabetes Mellitus (T2DM) is the most common form of diabetes mellitus and accounts for about 95% of all diabetes cases. Many newer oral as well as parenteral antidiabetic drugs have been introduced in to the market in recent years to control hyperglycemic conditions in diabetes patients and many of these drugs produce potential side effects in diabetes patients. Hence, this systematic review was aimed to analyze and compare the efficacy and safety of oral antidiabetic agents in controlling HbA1c in T2DM patients, that were approved by the United States-Food and Drug Administration (US-FDA) from 2013 to 2017. All randomized controlled, double-blind trials published in English during the search period involving the newer antidiabetic agents were selected. In the outcome assessment comparison, semaglutide demonstrated the highest efficacy in lowering HbA1c, with a 1.6% reduction (p < 0.0001) when given at a dose of 1.0 mg. The safety profile of all the agents as compared to placebo or control were similar, with no or slight increase in the occurrence of adverse events (AEs) but no fatal reaction was reported. The most common AEs of all the antidiabetic agents were gastrointestinal in nature, with several cases of hypoglycemic events. However, among all these agents, semaglutide seems to be the most efficacious drug to improve glycemic control in terms of HbA1c. Alogliptin has the least overall frequency of AEs compared to other treatment groups. Full article
Back to Top